サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1629180

糖尿病性胃不全麻痺の世界市場：タイプ別、治療法別、流通チャネル別、国別、地域別 - 産業分析、市場規模、市場シェア、予測（2024年～2032年）

Diabetic Gastroparesis Market, By Types, By Treatment, By Distribution Channel, By Country, and By Region - Industry Analysis, Market Size, Market Share & Forecast from 2024-2032

出版日
ページ情報
英文 303 Pages
納期
2～3営業日
カスタマイズ可能
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=143.57円
糖尿病性胃不全麻痺の世界市場：タイプ別、治療法別、流通チャネル別、国別、地域別 - 産業分析、市場規模、市場シェア、予測（2024年～2032年）
出版日: 2024年12月04日
発行: AnalystView Market Insights
ページ情報: 英文 303 Pages
納期: 2～3営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

レポートハイライト

世界の糖尿病性胃不全麻痺の市場規模は2023年に19億7,490万米ドルとなり、2024年～2032年にかけてCAGR4.30%で拡大すると予測されています。

糖尿病性胃不全麻痺市場：市場力学

糖尿病有病率の上昇が市場需要を急増させる

糖尿病患者数の増加が市場需要を牽引しており、国際糖尿病連合は2021年時点で世界の糖尿病患者数を5億3,700万人と報告しています。加えて、高齢化とライフスタイルの変化が糖尿病および胃不全麻痺患者の増加に寄与しており、関連治療市場が拡大しています。しかし、糖尿病患者の胃不全麻痺に対する認識は限られているため、早期診断と早期治療が制限され、市場成長に影響を与えています。逆に、胃不全麻痺治療薬の継続的な技術革新は、世界の糖尿病性胃不全麻痺市場の成長に有望な機会を提供しています。さらに、世界の高齢者人口の増加は、特に高齢の糖尿病患者に対する効果的な胃不全麻痺治療に対する需要を増加させます。

糖尿病性胃不全麻痺市場：主要洞察

当社のリサーチアナリストが共有した分析によると、世界市場は予測期間（2024～2032年）に約4.30％のCAGRで毎年成長すると推定されています。

タイプ別では、グレード3が2023年に最大市場シェアを示すと予測されています。

治療法別では、2023年には薬物治療が主要セグメントとなりました。

地域別では、北米が2023年に主要な収益源となりました。

糖尿病性胃不全麻痺市場：セグメンテーション分析：

糖尿病性胃不全麻痺の世界市場は、タイプ、治療法、流通チャネル、地域に基づいてセグメント化されます。

タイプ別では、グレード3（胃不全）とグレード2（代償性胃不全）の2つに分けられます。グレード3（胃不全）セグメントが市場を独占しています。より集中的な治療と管理オプションを必要とするこの病態の深刻な性質が、市場の高い需要を牽引しています。

市場は治療法によって外科治療と薬物治療の2つに分類されます。薬物治療セグメントは市場を独占しており、予測期間中もその優位性を維持するとみられます。外科手術に比べ侵襲性の低い選択肢を提供し、症状管理に効果的なプロキネティクスや制吐剤などの薬剤が含まれます。

糖尿病性胃不全麻痺市場：地理的洞察

地理的に、この市場は北米、ラテンアメリカ、欧州、アジア太平洋、中東・アフリカの地域に広がっています。これらの地域は、ビジネスをもたらす国によってさらに分けられます。

糖尿病性胃不全麻痺症市場：競合情勢

世界市場は、糖尿病患者の増加と的を絞った治療オプションの需要により拡大しています。各社は、患者の服薬アドヒアランスを高めるための製剤改良とともに、胃不全麻痺の症状に効果的に対処する革新的な治療法の開発に注力しています。戦略的提携、臨床試験、研究開発投資は、新規治療薬を市場に投入するために採用される中心的な戦略であり、新興市場でのアクセスを改善し、流通網を最適化するために地域提携を模索する企業もあります。

目次

第1章 糖尿病性胃不全麻痺市場の概要

  • 調査範囲
  • 市場推定年

第2章 エグゼクティブサマリー

  • 市場内訳
  • 競合考察

第3章 糖尿病性胃不全麻痺の主要市場動向

  • 市場促進要因
  • 市場抑制要因
  • 市場機会
  • 市場の将来動向

第4章 糖尿病性胃不全麻痺業界の調査

  • PEST分析
  • ポーターのファイブフォース分析
  • 成長見通しマッピング
  • 規制枠組み分析

第5章 糖尿病性胃不全麻痺市場：高まる地政学的緊張の影響

  • COVID-19パンデミックの影響
  • ロシア・ウクライナ戦争の影響
  • 中東紛争の影響

第6章 糖尿病性胃不全麻痺の市場情勢

  • 糖尿病性胃不全麻痺の市場シェア分析：2023年
  • 主要メーカー別内訳データ
    • 既存企業の分析
    • 新興企業の分析

第7章 糖尿病性胃不全麻痺市場：タイプ別

  • 概要
    • タイプ別のセグメントシェア分析
    • グレード3（胃不全）
    • グレード2（代償性胃不全）

第8章 糖尿病性胃不全麻痺市場：治療法別

  • 概要
    • 治療別のセグメントシェア分析
    • 外科治療
    • 薬物治療
      • 制吐剤
      • プロキネティクス
      • ボツリヌス
      • その他

第9章 糖尿病性胃不全麻痺市場：流通チャネル別

  • 概要
    • 流通チャネル別のセグメントシェア分析
    • オンライン薬局
    • 小売薬局
    • 院内薬局

第10章 糖尿病性胃不全麻痺市場：地域別

  • イントロダクション
  • 北米
    • 概要
    • 北米の主要メーカー
    • 米国
    • カナダ
  • 欧州
    • 概要
    • 欧州の主要メーカー
    • ドイツ
    • イタリア
    • 英国
    • フランス
    • ロシア
    • オランダ
    • スウェーデン
    • ポーランド
    • その他
  • アジア太平洋（APAC）
    • 概要
    • アジア太平洋の主要メーカー
    • インド
    • 中国
    • 日本
    • 韓国
    • オーストラリア
    • タイ
    • インドネシア
    • フィリピン
    • その他
  • ラテンアメリカ
    • 概要
    • ラテンアメリカの主要メーカー
    • ブラジル
    • メキシコ
    • アルゼンチン
    • コロンビア
    • その他
  • 中東・アフリカ
    • 概要
    • 中東・アフリカの主要メーカー
    • サウジアラビア
    • アラブ首長国連邦
    • イスラエル
    • トルコ
    • アルジェリア
    • エジプト
    • その他

第11章 主要ベンダー分析：糖尿病性胃不全麻痺業界

  • 競合ダッシュボード
    • 競合ベンチマーキング
    • 競合ポジショニング
  • 企業プロファイル
    • Theravance Biopharma
    • Allergan
    • Abbott
    • AstraZeneca
    • Evoke Pharma
    • Cadila Pharmaceuticals
    • Neurogastrx, Inc.
    • Eli Lilly and Company
    • Bausch Health
    • Teva Pharmaceutical Industries Ltd.
    • Alfa Wassermann SPA
    • Takeda Pharmaceutical Company Limited
    • Boston Scientific Corporation
    • Cardinal Health, Inc.
    • CR Bard, Inc.
    • Halyard Health, Inc.
    • Kimberly-Clark Corporation
    • Janssen Global Services, LLC
    • Medtronic
    • Rhythm Pharmaceuticals, Inc.
    • その他

第12章 アナリストの全方位展望

目次
Product Code: ANV4440

REPORT HIGHLIGHT

Diabetic gastroparesis market size was valued at USD 1,974.90 Million in 2023, expanding at a CAGR of 4.30% from 2024 to 2032.

Diabetic Gastroparesis is a digestive disorder where diabetes damages the vagus nerve, slowing stomach muscle function. This impairs stomach emptying, causing food to remain longer than normal, leading to symptoms like nausea, bloating, vomiting, and fluctuating blood sugar levels. It is common in individuals with long-term or poorly controlled diabetes, particularly type 1. Managing it involves dietary adjustments, blood sugar control, and, in some cases, medications or other therapies.

Diabetic Gastroparesis Market- Market Dynamics

Rising prevalence of diabetes to surge the market demand

The increasing number of diabetes cases is driving market demand, with International Diabetes federation reporting 537 million global diabetes cases as of 2021. Besides, an aging population and lifestyle changes contribute to more diabetes and gastroparesis cases, expanding the market for related treatments. However, limited awareness among diabetic patients about gastroparesis restricts early diagnosis and treatment, affecting market growth. On the contrary, continuous innovation in gastroparesis drug therapies offers promising opportunities for the global diabetic gastroparesis market growth. Furthermore, the rising geriatric population worldwide increases the demand for effective gastroparesis treatments, especially for elderly diabetes patients.

Diabetic Gastroparesis Market- Key Insights

As per the analysis shared by our research analyst, the global market is estimated to grow annually at a CAGR of around 4.30% over the forecast period (2024-2032)

Based on types segmentation, grade 3 was predicted to show maximum market share in the year 2023

Based on treatment segmentation, pharmacological treatment was the leading segment in 2023

On the basis of region, North America was the leading revenue generator in 2023

Diabetic Gastroparesis Market- Segmentation Analysis:

The Global Diabetic Gastroparesis Market is segmented on the basis of Types, Treatment, Distribution Channel, and Region.

The market is divided into two categories based on types: grade 3 (gastric failure) and grade 2 (compensated gastroparesis). The grade 3 (gastric failure) sector dominates the market. The severe nature of this condition, which demands more intensive treatment and management options is driving higher demand in the market.

The market is divided into two categories based on treatment: surgery and pharmacological treatment. The pharmacological treatment sector dominates the market and is likely to maintain its dominance during the forecast period. It offers less invasive options compared to surgery and includes a range of drugs like prokinetics and antiemetics, which are effective in symptom management.

Diabetic Gastroparesis Market- Geographical Insights

Geographically, this market is widespread into the regions of North America, Latin America, Europe, Asia Pacific, and the Middle East and Africa. These regions are further divided as per the nations bringing business.

Diabetic Gastroparesis Market- Competitive Landscape:

The global market is expanding due to rising cases of diabetes and the demand for targeted treatment options. Companies are focusing on developing innovative therapies that address gastroparesis symptoms effectively, alongside improving drug formulations to enhance patient adherence. Strategic collaborations, clinical trials, and R&D investments are core strategies employed to bring novel treatments to market, while some companies explore regional partnerships to improve access in emerging markets and optimize distribution networks.

Recent Developments:

In June 2024, Renexxion Ireland Limited received FDA approval for an Investigational New Drug (IND) application for naronapride, an oral medication designed to treat gastroparesis. This promising drug aims to address symptoms associated with slow gastric emptying, such as nausea and vomiting, advancing treatment options for gastrointestinal disorders.

SCOPE OF THE REPORT

The scope of this report covers the market by its major segments, which include as follows:

GLOBAL DIABETIC GASTROPARESIS MARKET KEY PLAYERS- DETAILED COMPETITIVE INSIGHTS

  • Theravance Biopharma
  • Allergan
  • Abbott
  • AstraZeneca
  • Evoke Pharma
  • Cadila Pharmaceuticals
  • Neurogastrx, Inc.
  • Eli Lilly and Company
  • Bausch Health
  • Teva Pharmaceutical Industries Ltd.
  • Alfa Wassermann SPA
  • Takeda Pharmaceutical Company Limited
  • Boston Scientific Corporation
  • Cardinal Health, Inc.
  • C. R. Bard, Inc.
  • Halyard Health, Inc.
  • Kimberly-Clark Corporation
  • Janssen Global Services, LLC
  • Medtronic
  • Rhythm Pharmaceuticals, Inc.
  • Others

GLOBAL DIABETIC GASTROPARESIS MARKET, BY TYPES- MARKET ANALYSIS, 2019 - 2032

  • Grade 3 (Gastric Failure)
  • Grade 2 (Compensated Gastroparesis)

GLOBAL DIABETIC GASTROPARESIS MARKET, BY TREATMENT- MARKET ANALYSIS, 2019 - 2032

  • Surgical
  • Pharmacological Treatment
  • Antiemetic Agents
  • Prokinetics
  • Botulinum
  • Others

GLOBAL DIABETIC GASTROPARESIS MARKET, BY DISTRIBUTION CHANNEL- MARKET ANALYSIS, 2019 - 2032

  • Online Pharmacies
  • Retail Pharmacies
  • Hospital Pharmacies

GLOBAL DIABETIC GASTROPARESIS MARKET, BY REGION- MARKET ANALYSIS, 2019 - 2032

  • North America
  • The U.S.
  • Canada
  • Europe
  • Germany
  • France
  • Italy
  • Spain
  • United Kingdom
  • Russia
  • Netherlands
  • Sweden
  • Poland
  • Rest of Europe
  • Asia Pacific
  • India
  • China
  • South Korea
  • Japan
  • Australia
  • Thailand
  • Indonesia
  • Philippines
  • Rest of APAC
  • Latin America
  • Brazil
  • Mexico
  • Argentina
  • Colombia
  • Rest of LATAM
  • The Middle East and Africa
  • Saudi Arabia
  • United Arab Emirates
  • Israel
  • Turkey
  • Algeria
  • Egypt
  • Rest of MEA

Table of Contents

1. Diabetic Gastroparesis Market Overview

  • 1.1. Study Scope
  • 1.2. Market Estimation Years

2. Executive Summary

  • 2.1. Market Snippet
    • 2.1.1. Diabetic Gastroparesis Market Snippet by Types
    • 2.1.2. Diabetic Gastroparesis Market Snippet by Treatment
    • 2.1.3. Diabetic Gastroparesis Market Snippet by Distribution Channel
    • 2.1.4. Diabetic Gastroparesis Market Snippet by Country
    • 2.1.5. Diabetic Gastroparesis Market Snippet by Region
  • 2.2. Competitive Insights

3. Diabetic Gastroparesis Key Market Trends

  • 3.1. Diabetic Gastroparesis Market Drivers
    • 3.1.1. Impact Analysis of Market Drivers
  • 3.2. Diabetic Gastroparesis Market Restraints
    • 3.2.1. Impact Analysis of Market Restraints
  • 3.3. Diabetic Gastroparesis Market Opportunities
  • 3.4. Diabetic Gastroparesis Market Future Trends

4. Diabetic Gastroparesis Industry Study

  • 4.1. PEST Analysis
  • 4.2. Porter's Five Forces Analysis
  • 4.3. Growth Prospect Mapping
  • 4.4. Regulatory Framework Analysis

5. Diabetic Gastroparesis Market: Impact of Escalating Geopolitical Tensions

  • 5.1. Impact of COVID-19 Pandemic
  • 5.2. Impact of Russia-Ukraine War
  • 5.3. Impact of Middle East Conflicts

6. Diabetic Gastroparesis Market Landscape

  • 6.1. Diabetic Gastroparesis Market Share Analysis, 2023
  • 6.2. Breakdown Data, by Key Manufacturer
    • 6.2.1. Established Players' Analysis
    • 6.2.2. Emerging Players' Analysis

7. Diabetic Gastroparesis Market - By Types

  • 7.1. Overview
    • 7.1.1. Segment Share Analysis, By Types, 2023 & 2032 (%)
    • 7.1.2. Grade 3 (Gastric Failure)
    • 7.1.3. Grade 2 ( Compensated Gastroparesis)

8. Diabetic Gastroparesis Market - By Treatment

  • 8.1. Overview
    • 8.1.1. Segment Share Analysis, By Treatment, 2023 & 2032 (%)
    • 8.1.2. Surgery
    • 8.1.3. Pharmacological Treatment
      • 8.1.3.1. Antiemetic Agents
      • 8.1.3.2. Prokinetics
      • 8.1.3.3. Botulinum
      • 8.1.3.4. Others

9. Diabetic Gastroparesis Market - By Distribution Channel

  • 9.1. Overview
    • 9.1.1. Segment Share Analysis, By Distribution Channel, 2023 & 2032 (%)
    • 9.1.2. Online Pharmacies
    • 9.1.3. Retail Pharmacies
    • 9.1.4. Hospital Pharmacies

10. Diabetic Gastroparesis Market- By Geography

  • 10.1. Introduction
    • 10.1.1. Segment Share Analysis, By Geography, 2023 & 2032 (%)
  • 10.2. North America
    • 10.2.1. Overview
    • 10.2.2. Diabetic Gastroparesis Key Manufacturers in North America
    • 10.2.3. North America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 10.2.4. North America Market Size and Forecast, By Types, 2019 - 2032 (US$ Million)
    • 10.2.5. North America Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
    • 10.2.6. North America Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.2.7. U.S.
      • 10.2.7.1. Overview
      • 10.2.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.2.7.3. U.S. Market Size and Forecast, By Types, 2019 - 2032 (US$ Million)
      • 10.2.7.4. U.S. Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
      • 10.2.7.5. U.S. Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.2.8. Canada
      • 10.2.8.1. Overview
      • 10.2.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.2.8.3. Canada Market Size and Forecast, By Types, 2019 - 2032 (US$ Million)
      • 10.2.8.4. Canada Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
      • 10.2.8.5. Canada Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  • 10.3. Europe
    • 10.3.1. Overview
    • 10.3.2. Diabetic Gastroparesis Key Manufacturers in Europe
    • 10.3.3. Europe Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 10.3.4. Europe Market Size and Forecast, By Types, 2019 - 2032 (US$ Million)
    • 10.3.5. Europe Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
    • 10.3.6. Europe Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.3.7. Germany
      • 10.3.7.1. Overview
      • 10.3.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.7.3. Germany Market Size and Forecast, By Types, 2019 - 2032 (US$ Million)
      • 10.3.7.4. Germany Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
      • 10.3.7.5. Germany Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.3.8. Italy
      • 10.3.8.1. Overview
      • 10.3.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.8.3. Italy Market Size and Forecast, By Types, 2019 - 2032 (US$ Million)
      • 10.3.8.4. Italy Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
      • 10.3.8.5. Italy Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.3.9. United Kingdom
      • 10.3.9.1. Overview
      • 10.3.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.9.3. United Kingdom Market Size and Forecast, By Types, 2019 - 2032 (US$ Million)
      • 10.3.9.4. United Kingdom Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
      • 10.3.9.5. United Kingdom Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.3.10. France
      • 10.3.10.1. Overview
      • 10.3.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.10.3. France Market Size and Forecast, By Types, 2019 - 2032 (US$ Million)
      • 10.3.10.4. France Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
      • 10.3.10.5. France Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.3.11. Russia
      • 10.3.11.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.11.2. Russia Market Size and Forecast, By Types, 2019 - 2032 (US$ Million)
      • 10.3.11.3. Russia Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
      • 10.3.11.4. Russia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.3.12. Netherlands
      • 10.3.12.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.12.2. Netherlands Market Size and Forecast, By Types, 2019 - 2032 (US$ Million)
      • 10.3.12.3. Netherlands Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
      • 10.3.12.4. Netherlands Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.3.13. Sweden
      • 10.3.13.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.13.2. Sweden Market Size and Forecast, By Types, 2019 - 2032 (US$ Million)
      • 10.3.13.3. Sweden Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
      • 10.3.13.4. Sweden Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.3.14. Poland
      • 10.3.14.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.14.2. Poland Market Size and Forecast, By Types, 2019 - 2032 (US$ Million)
      • 10.3.14.3. Poland Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
      • 10.3.14.4. Poland Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.3.15. Rest of Europe
      • 10.3.15.1. Overview
      • 10.3.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.15.3. Rest of the Europe Market Size and Forecast, By Types, 2019 - 2032 (US$ Million)
      • 10.3.15.4. Rest of the Europe Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
      • 10.3.15.5. Rest of the Europe Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  • 10.4. Asia Pacific (APAC)
    • 10.4.1. Overview
    • 10.4.2. Diabetic Gastroparesis Key Manufacturers in Asia Pacific
    • 10.4.3. Asia Pacific Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 10.4.4. Asia Pacific Market Size and Forecast, By Types, 2019 - 2032 (US$ Million)
    • 10.4.5. Asia Pacific Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
    • 10.4.6. Asia Pacific Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.4.7. India
      • 10.4.7.1. Overview
      • 10.4.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.7.3. India Market Size and Forecast, By Types, 2019 - 2032 (US$ Million)
      • 10.4.7.4. India Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
      • 10.4.7.5. India Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.4.8. China
      • 10.4.8.1. Overview
      • 10.4.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.8.3. China Market Size and Forecast, By Types, 2019 - 2032 (US$ Million)
      • 10.4.8.4. China Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
      • 10.4.8.5. China Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.4.9. Japan
      • 10.4.9.1. Overview
      • 10.4.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.9.3. Japan Market Size and Forecast, By Types, 2019 - 2032 (US$ Million)
      • 10.4.9.4. Japan Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
      • 10.4.9.5. Japan Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.4.10. South Korea
      • 10.4.10.1. Overview
      • 10.4.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.10.3. South Korea Market Size and Forecast, By Types, 2019 - 2032 (US$ Million)
      • 10.4.10.4. South Korea Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
      • 10.4.10.5. South Korea Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.4.11. Australia
      • 10.4.11.1. Overview
      • 10.4.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.11.3. Australia Market Size and Forecast, By Types, 2019 - 2032 (US$ Million)
      • 10.4.11.4. Australia Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
      • 10.4.11.5. Australia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.4.12. Thailand
      • 10.4.12.1. Overview
      • 10.4.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.12.3. Thailand Market Size and Forecast, By Types, 2019 - 2032 (US$ Million)
      • 10.4.12.4. Thailand Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
      • 10.4.12.5. Thailand Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.4.13. Indonesia
      • 10.4.13.1. Overview
      • 10.4.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.13.3. Indonesia Market Size and Forecast, By Types, 2019 - 2032 (US$ Million)
      • 10.4.13.4. Indonesia Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
      • 10.4.13.5. Indonesia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.4.14. Philippines
      • 10.4.14.1. Overview
      • 10.4.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.14.3. Philippines Market Size and Forecast, By Types, 2019 - 2032 (US$ Million)
      • 10.4.14.4. Philippines Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
      • 10.4.14.5. Philippines Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.4.15. Rest of APAC
      • 10.4.15.1. Overview
      • 10.4.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.15.3. Rest of APAC Market Size and Forecast, By Types, 2019 - 2032 (US$ Million)
      • 10.4.15.4. Rest of APAC Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
      • 10.4.15.5. Rest of APAC Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  • 10.5. Latin America
    • 10.5.1. Overview
    • 10.5.2. Diabetic Gastroparesis Key Manufacturers in Latin America
    • 10.5.3. Latin America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 10.5.4. Latin America Market Size and Forecast, By Types, 2019 - 2032 (US$ Million)
    • 10.5.5. Latin America Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
    • 10.5.6. Latin America Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.5.7. Brazil
      • 10.5.7.1. Overview
      • 10.5.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.5.7.3. Brazil Market Size and Forecast, By Types, 2019 - 2032 (US$ Million)
      • 10.5.7.4. Brazil Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
      • 10.5.7.5. Brazil Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.5.8. Mexico
      • 10.5.8.1. Overview
      • 10.5.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.5.8.3. Mexico Market Size and Forecast, By Types, 2019 - 2032 (US$ Million)
      • 10.5.8.4. Mexico Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
      • 10.5.8.5. Mexico Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.5.9. Argentina
      • 10.5.9.1. Overview
      • 10.5.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.5.9.3. Argentina Market Size and Forecast, By Types, 2019 - 2032 (US$ Million)
      • 10.5.9.4. Argentina Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
      • 10.5.9.5. Argentina Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.5.10. Colombia
      • 10.5.10.1. Overview
      • 10.5.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.5.10.3. Colombia Market Size and Forecast, By Types, 2019 - 2032 (US$ Million)
      • 10.5.10.4. Colombia Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
      • 10.5.10.5. Colombia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.5.11. Rest of LATAM
      • 10.5.11.1. Overview
      • 10.5.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.5.11.3. Rest of LATAM Market Size and Forecast, By Types, 2019 - 2032 (US$ Million)
      • 10.5.11.4. Rest of LATAM Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
      • 10.5.11.5. Rest of LATAM Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  • 10.6. Middle East and Africa
    • 10.6.1. Overview
    • 10.6.2. Diabetic Gastroparesis Key Manufacturers in Middle East and Africa
    • 10.6.3. Middle East and Africa Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 10.6.4. Middle East and Africa Market Size and Forecast, By Types, 2019 - 2032 (US$ Million)
    • 10.6.5. Middle East and Africa Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
    • 10.6.6. Middle East and Africa Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.6.7. Saudi Arabia
      • 10.6.7.1. Overview
      • 10.6.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.7.3. Saudi Arabia Market Size and Forecast, By Types, 2019 - 2032 (US$ Million)
      • 10.6.7.4. Saudi Arabia Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
      • 10.6.7.5. Saudi Arabia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.6.8. United Arab Emirates
      • 10.6.8.1. Overview
      • 10.6.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.8.3. United Arab Emirates Market Size and Forecast, By Types, 2019 - 2032 (US$ Million)
      • 10.6.8.4. United Arab Emirates Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
      • 10.6.8.5. United Arab Emirates Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.6.9. Israel
      • 10.6.9.1. Overview
      • 10.6.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.9.3. Israel Market Size and Forecast, By Types, 2019 - 2032 (US$ Million)
      • 10.6.9.4. Israel Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
      • 10.6.9.5. Israel Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.6.10. Turkey
      • 10.6.10.1. Overview
      • 10.6.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.10.3. Turkey Market Size and Forecast, By Types, 2019 - 2032 (US$ Million)
      • 10.6.10.4. Turkey Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
      • 10.6.10.5. Turkey Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.6.11. Algeria
      • 10.6.11.1. Overview
      • 10.6.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.11.3. Algeria Market Size and Forecast, By Types, 2019 - 2032 (US$ Million)
      • 10.6.11.4. Algeria Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
      • 10.6.11.5. Algeria Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.6.12. Egypt
      • 10.6.12.1. Overview
      • 10.6.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.12.3. Egypt Market Size and Forecast, By Types, 2019 - 2032 (US$ Million)
      • 10.6.12.4. Egypt Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
      • 10.6.12.5. Egypt Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.6.13. Rest of MEA
      • 10.6.13.1. Overview
      • 10.6.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.13.3. Rest of MEA Market Size and Forecast, By Types, 2019 - 2032 (US$ Million)
      • 10.6.13.4. Rest of MEA Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
      • 10.6.13.5. Rest of MEA Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)

11. Key Vendor Analysis- Diabetic Gastroparesis Industry

  • 11.1. Competitive Dashboard
    • 11.1.1. Competitive Benchmarking
    • 11.1.2. Competitive Positioning
  • 11.2. Company Profiles
    • 11.2.1. Theravance Biopharma
    • 11.2.2. Allergan
    • 11.2.3. Abbott
    • 11.2.4. AstraZeneca
    • 11.2.5. Evoke Pharma
    • 11.2.6. Cadila Pharmaceuticals
    • 11.2.7. Neurogastrx, Inc.
    • 11.2.8. Eli Lilly and Company
    • 11.2.9. Bausch Health
    • 11.2.10. Teva Pharmaceutical Industries Ltd.
    • 11.2.11. Alfa Wassermann SPA
    • 11.2.12. Takeda Pharmaceutical Company Limited
    • 11.2.13. Boston Scientific Corporation
    • 11.2.14. Cardinal Health, Inc.
    • 11.2.15. C. R. Bard, Inc.
    • 11.2.16. Halyard Health, Inc.
    • 11.2.17. Kimberly-Clark Corporation
    • 11.2.18. Janssen Global Services, LLC
    • 11.2.19. Medtronic
    • 11.2.20. Rhythm Pharmaceuticals, Inc.
    • 11.2.21. Others

12. 360 Degree Analyst View

13. Appendix

  • 13.1. Research Methodology
  • 13.2. References
  • 13.3. Abbreviations
  • 13.4. Disclaimer
  • 13.5. Contact Us